# EMA and Quad-Agonist Approvals in Europe: A Pipeline Outlook

Canonical source: https://retacompare.com/research/ema-and-quad-agonist-approvals-in-europe

Pipeline Outlook · 2026-05-02


    The European regulatory landscape is poised for potential shifts as various quad-agonist candidates progress through clinical trials. These developments follow the emergence of multi-agonists like Retatrutide, which is currently in Phase 3 trials.


The big picture

The landscape of obesity and metabolic disorder treatments is evolving rapidly, particularly following the introduction of multi-agonist therapies. Retatrutide (LY3437943), a triple agonist targeting GLP-1, GIP, and glucagon receptors, is currently in Phase 3 clinical trials. The anticipation surrounding its potential efficacy is paving the way for further exploration into quad-agonist and even penta-agonist therapies. These next-generation agents aim to enhance metabolic outcomes by simultaneously modulating multiple pathways associated with energy balance and glucose homeostasis.


How it works

Multi-agonist therapies like Retatrutide leverage the synergistic effects of multiple hormone receptors. GLP-1 and GIP are well-established incretins that enhance insulin secretion and improve glycemic control. Glucagon, on the other hand, plays a crucial role in energy expenditure and appetite regulation. By activating these pathways, multi-agonists are hypothesized to promote significant weight loss and improve metabolic health. Quad-agonists, which would theoretically add another receptor target, could further enhance these effects, though their specific mechanisms remain under investigation.


Key points at a glance

Retatrutide is a triple agonist currently in Phase 3 trials.

Tirzepatide is an approved dual agonist targeting GLP-1 and GIP.

Quad-agonist candidates are still in early clinical or preclinical stages.

Examples of dual agonists include Mazdutide, Survodutide, and Pemvidutide.

Current research is exploring combinations targeting additional receptors to improve efficacy.

No quad-agonist or penta-agonist has been approved as of now.

The European Medicines Agency (EMA) will play a critical role in evaluating these new therapies.


Where this fits in the pipeline

Several companies are investigating quad-agonist candidates, although most are still in early clinical stages. For instance, HM15275 from Hanmi and CT-388 from Roche/Carmot are among the programs being studied. These candidates aim to build on the insights gained from existing dual and triple agonists, with the goal of achieving enhanced metabolic effects. The timelines for these programs are not definitively established, but early data from ongoing studies will likely inform regulatory strategies in Europe.


What it could mean for patients

If successful, quad-agonists could offer patients more effective treatment options for obesity and metabolic disorders. The potential to target multiple pathways may lead to improved weight management and better glycemic control compared to current therapies. However, the actual clinical impact will depend on the outcomes of ongoing trials and the subsequent regulatory assessments. Patient safety and long-term effects will also be critical considerations in the post-approval monitoring phase.


Open questions and what we don't yet know

Many uncertainties remain regarding the development of quad-agonists. Key questions include their safety profiles, optimal dosing regimens, and the specific receptors that will be targeted. Additionally, the regulatory landscape for these new therapies is still evolving, and the EMA's criteria for approval will be crucial. As research progresses, understanding the pharmacodynamics and potential adverse effects will be essential for both clinicians and patients.


Bottom line

The exploration of quad-agonist therapies represents a promising frontier in obesity and metabolic disorder treatment, following the advancements made by Retatrutide and others. Continued research and regulatory oversight will be vital in determining their future role in clinical practice.


This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources